Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecular marker for diagnosing chronic obstructive pulmonary disease

A technology for chronic obstructive pulmonary disease and substances, applied in the fields of disease diagnosis, material analysis, biological testing, etc., can solve problems such as clinical misdiagnosis, and achieve the effect of improving survival rate

Inactive Publication Date: 2018-07-20
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, more and more evidence has found that using FEV1 / FVC<0.70 as the diagnostic standard of COPD can lead to a large number of clinical misdiagnosis, and the current diagnostic standard is facing unprecedented challenges

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker for diagnosing chronic obstructive pulmonary disease
  • Molecular marker for diagnosing chronic obstructive pulmonary disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Screening of differentially expressed genes in patients with chronic obstructive pulmonary disease and normal people

[0042] 1. Clinical research objects:

[0043] Five patients with chronic obstructive pulmonary disease were selected, including 2 males and 3 females, ranging in age from 50 to 79 years old. The diagnostic criteria were in compliance with the "Chronic Obstructive Pulmonary Disease Diagnosis and Treatment Norms" revised in 2007.

[0044] Diagnostic criteria: Any patient suffering from dyspnea, chronic cough or sputum, and a history of exposure to risk factors, lung function tests show that after inhalation of bronchodilators, there is airflow limitation, which can be diagnosed as COPD.

[0045] Exclusion criteria: ①Patients with other lung diseases, such as bronchial asthma, pulmonary fibrosis, lung cancer, etc.; ②Patients with other infections; ③With severe cardiovascular and cerebrovascular diseases, diabetes, blood system diseases, malignant tumors, ...

Embodiment 2

[0085] Example 2 QPCR verification of the relationship between candidate genes and chronic obstructive pulmonary disease

[0086] Based on the results of previous high-throughput sequencing, and according to the size of P value, we selected the GMFG gene (its expression is up-regulated in patients with chronic obstructive pulmonary disease) for verification.

[0087] 1. Research objects:

[0088] According to the method of Example 1, 45 patients with chronic obstructive pulmonary disease and 35 normal persons were selected.

[0089] 2. Extraction of total RNA from blood

[0090] Use Biotech blood RNA extraction kit to extract total RNA from blood:

[0091] (1) Take 250μl (or 0.25g) of whole blood into the RNase-Free filter column, centrifuge at 13000rpm for 2 minutes, collect the lower liquid, and add 0.75ml lysis buffer RLS.

[0092] (2) Vigorously shake the homogenized sample and mix it, and incubate it at 15-30°C for 5 minutes to completely decompose the ribosome.

[0093] (3) Optional ...

Embodiment 3

[0109] Example 3 Western blotting experiments to verify the expression products of differentially expressed genes in patients with chronic obstructive pulmonary disease and normal people

[0110] 1. Clinical object: Same as Example 2.

[0111] 2. Separation of monocytes

[0112] For patients with chronic obstructive pulmonary disease and normal people, take 10ml of venous blood, inject it into a sterile vial containing heparin, and shake it gently after capping. Use a sterile pipette to add an equal volume of HBSS (NaCl 8.0g, Na 2 HPO 4 0.132g, KH 2 PO 4 0.06g, KCl 0.4g, phenol red 1ml, NaHCO 3 0.35g, D-glucose 1.0g, dissolved in 1000ml double distilled water) to reduce the aggregation of red blood cells. Aspirate 8ml lymphocyte layering solution and place it in a 50ml centrifuge tube. Add diluted blood slowly along the tube wall to keep the interface clear. Do not mix the two. Centrifuge at 2000r / min for 30min at 20℃. Carefully draw the layered solution and connect it with plasma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a molecular marker for diagnosing a chronic obstructive pulmonary disease. The gene marker is a GMFG gene. Through detecting levels of the GMFG gene and GMFG proteins in bloodof a testee, whether the testee suffers from the chronic obstructive pulmonary disease can be judged or whether the testee is at risk of the chronic obstructive pulmonary disease can be judged. According to the GMFG gene and the GMFG proteins, a product for diagnosing the chronic obstructive pulmonary disease through detecting the GMFG gene or the content of the GMFG proteins can be developed; thediagnostic product can be popularized and used in clinic.

Description

Technical field [0001] The present invention relates to the field of chronic obstructive pulmonary disease diagnosis. More specifically, the present invention relates to GMFG gene as a diagnostic tool for chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a common and frequently-occurring disease in the respiratory department. It is also an internationally recognized chronic pulmonary disease that seriously threatens people's health. Its morbidity and mortality are high, and it seriously increases the economic burden of people and society. According to statistics from the World Health Organization, COPD was the fourth leading cause of death in the world in 2000 (Aibek E Mirrakhimov. Chronicobstructive pulmonary disease and glucose metabolism: a bitter sweetsymphony. Cardiovasc Diabetol, 2012, 11: 132). It is expected that by 2020, COPD will be It has risen to the third leading cause of death and the fifth leading c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/53C12Q1/6883
CPCC12Q1/6883C12Q2600/156G01N33/5308G01N33/6857G01N33/6884G01N2800/122
Inventor 向常娟马翠
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com